-
The future can be expected - "Late Non-small Cell Lung Cancer Anti-angiogenesis Drug Treatment Chinese Expert Consensus (2022 Edition)" officially released!
Time of Update: 2022-10-12
The "Consensus" is based on the 2020 edition, revised by the expert group based on the new evidence published in recent years, combined with clinical experience, to guide the rational use of anti-angiogenesis drugs in the clinical departments of lung cancer treatment in China, and further improve the standardized diagnosis and treatment level of lung cancer in China.
-
European Radiology: Enhancement of digital mammography in women with dense mammary parenchyma
Time of Update: 2022-10-12
To our knowledge, to date, only a few small-sample-sized, single-institution studies support the use of CEM in dense mammary glands such as Asian women.
To our knowledge, to date, only a few small-sample-sized, single-institution studies support the use of CEM in dense mammary glands such as Asian women.
-
Blood: Outcome after failure of anti-CD19 CAR-T cell therapy in patients with aggressive B-cell lymphoma
Time of Update: 2022-10-12
2022016945 Anti-CD19 CAR-T cell therapy represents a major advance in the treatment of relapsed/refractory sexually aggressive B-cell lymphoma.
2022016945 Anti-CD19 CAR-T cell therapy represents a major advance in the treatment of relapsed/refractory sexually aggressive B-cell lymphoma.
-
Nat Metab: Professor Wu Qiao's team reveals a new mechanism by which hepatic stellate cell exohexohrokinase HK1 accelerates the process of liver cancer
Time of Update: 2022-10-12
Hepatocellular carcinoma (HCC) is the most common hepatic malignancy, and more than 80% of clinical liver cancers are developed from liver fibrosis or cirrhosis, suggesting that liver fibrosis can dir
-
European Radiology: Enhanced CT for quantitative analysis of pancreatic neuroendocrine tumors
Time of Update: 2022-10-12
In this study, the mean artery/portal vein absolute enhancement values of PNECs (19.
In this study, the mean artery/portal vein absolute enhancement values of PNECs (19.
In this study, the mean artery/portal vein absolute enhancement values of PNECs (19.
-
European Radiology: Imaging assessment of extrarectal space lymph nodes for rectal cancer
Time of Update: 2022-10-12
A recent study, published in the journal European Radiology, explored differences in diagnostic opinion among radiologists when measuring LLN short axis size, anatomical position, and determining whether LLN is suspicious, and assessed whether assisted specialized training could significantly improve the magnitude of this difference.
-
Easy access to imaging manifestations of gallbladder cancer
Time of Update: 2022-10-12
Gallbladder polypsTypical casesCase 1 Case 2 Case 3 Gallbladder Carcinoma occurs in the epithelial cells of the gallbladder floor, body, neck and cystic duct; the incidence accounts for 2/3 of biliary tract tumors .
-
Easy access to imaging manifestations of gallbladder cancer
Time of Update: 2022-10-12
Gallbladder polypsTypical casesCase 1 Case 2 Case 3 Gallbladder Carcinoma occurs in the epithelial cells of the gallbladder floor, body, neck and cystic duct; the incidence accounts for 2/3 of biliary tract tumors .
-
Eur Urol Oncol: Comparison of the detection of clinically significant prostate cancer with a four-core targeted biopsy versus a nine-core targeted saturation biopsy for transperineal prostate fusion biopsy
Time of Update: 2022-10-12
Sep 2022 Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TB) help accurately detect clinically significant prostate cancer (csPC).
Sep 2022 Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TB) help accurately detect clinically significant prostate cancer (csPC).
-
Professor Zhi Xiuyi: The gains and losses of early screening for lung cancer under the new crown shroud
Time of Update: 2022-10-12
The small pulmonary nodules and suspected early lung cancer populations screened out by artificial intelligence technology, and then further clinical confirmation through the cooperation of multidisciplinary doctors such as imaging, thoracic surgery, respiratory and oncology, the work efficiency and diagnostic accuracy have been greatly improved.
-
Resistance mechanisms and treatment options for third-generation EGFR and ALK-TKI in the treatment of non-small cell lung cancer
Time of Update: 2022-10-12
prefaceAccording to the national cancer report released by the National Cancer Center in 2022, there were about 828,000 new lung cancer cases and 657,000 deaths in China in 2016, which is the highest
-
The latest breakthrough in the field of oncology! New wearable devices monitor tumor size in real time
Time of Update: 2022-10-12
The results showed that compared to other measurement techniques that take days to discern significant biological differences, FAST sensors can monitor changes in tumor volume expansion or contraction almost immediately after receiving drug treatment.
-
Mobozantinib is used in patients with positive EGFR exon 20 insertion mutations, significantly prolonging survival!
Time of Update: 2022-10-12
EGFR (Epidermal Growth Factor Receptor) is no stranger to cancer patients and is the most common driver gene for non-small cell lung cancer, especially in up to 60% of lung adenocarcinomas. EGFR mutat
-
Science sub-journal: Circadian rhythm disorders increase the risk of cancer, and body temperature plays an important role in this
Time of Update: 2022-10-12
Lamia of the Scripps Research Institute published a research paper titled Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer in Science Advances。The study revealed that the link between circadian rhythm disorders and cancer is related to body temperature, suggesting that chronic increases in signaling by members of the heat shock protein family may be a key molecular link between circadian rhythm disorders and increased cancer risk.
-
"Cell": Scientists reveal immune profiles of different tumor types
Time of Update: 2022-10-12
In a study titled "Discovering dominant tumor immune archetypes in a pan-cancer census" published in Cell, UCSF and multiple research teams identified and classified immune archetypes in 12 different tumor types.
-
2022 Nobel Laureate in Chemistry: Using chemical technology to disrupt cancer treatment, founding the company with hundreds of millions of dollars in financing, and has launched clinical trials
Time of Update: 2022-10-12
Based on these findings, Carolyn Bertozzi founded a biotechnology company called Palleon Pharmaceuticals in 2015 to develop sugar-mediated immunomodulation for cancer and inflammatory diseases, such as the formation of sialidase with PD-L1 or HER2 antibodies to form fusion proteins for a two-pronged anti-cancer effect 。 The company has completed approximately $150 million in financing, of which the bifunctional sialidase fusion protein drug E-602, which targets immunosuppressive sialigans, on tumor cells and immune cells, is already in Phase 1/2 clinical study.
-
European Radiology: How exactly should papillary thyroid cancer be treated? Oscillation between microwave ablation and surgical treatment
Time of Update: 2022-10-12
Recently, a study published in the journal European Radiology compared the safety and efficacy of microwave ablation (MWA) and open surgical treatment on mETE T1N0M0 PTC detected by ultrasound, providing a reference for clinical selection of the best treatment regimen.
-
15 common malignant pulmonary nodules imaging features are recommended for collection
Time of Update: 2022-10-12
The meaning to be expressed is that the lesion is very close to the pleura, but there is a very small gap, indicating: With the increase in the number of pulmonary nodules found in the examination, their benign and malignant judgments are mainly based on the performance of chest CT images.
-
Lancet Oncol: COSMIC-312 – The Mystery of Liver Cancer Immunotherapy
Time of Update: 2022-10-12
It is also interesting to wonder why there is no difference in mOS and the low overall response rate in the combination therapy group (47 out of 432 [11%]), suggesting that the single-agent activity of each drug may not be sufficient to ensure clinical synergistic effectsCOSMIC-312The results of the COSMIC-312 trial were published on NEJM and Lance oncology, see: Which is stronger in the first-line treatment of advanced liver cancer?
-
J Clin Oncol: advanced melanoma with nivolumab combined with ipizumab vs nivolumab therapy
Time of Update: 2022-10-12
The Phase 3 CheckMate 915 trial evaluated the efficacy and safety of adjuvant nalvozumab combined with ipizumab vs nalvolumab monotherapy in patients with resected stage IIIB-D or IV melanoma.
